Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : INCY) sees Significant Insider Selling Continuing

04/01/2021 | 10:21pm EDT


© MT Newswires 2021
All news about INCYTE CORPORATION
05/17SECTOR UPDATE : Health Care Stocks Fall Premarket Monday
MT
05/17INCYTE  : Late-Stage Studies on Ruxolitinib Cream as Potential Vitiligo Therapy ..
MT
05/17INCYTE  : vitiligo treatment meets main goal in late-stage trial
RE
05/17INCYTE  : vitiligo treatment meets main goal in late-stage trial
RE
05/17INCYTE  : Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxo..
BU
05/12INCYTE  : Data From Incyte's Oncology Portfolio Accepted for Presentation at the..
BU
05/12INCYTE  : MorphoSys Dose First Patient in Late-Stage Study of Lymphoma Drug Cand..
MT
05/11PRESS RELEASE  : MorphoSys and Incyte Announce -3-
DJ
05/11PRESS RELEASE  : MorphoSys and Incyte Announce -2-
DJ
05/11PRESS RELEASE  : MorphoSys and Incyte Announce First Patient Dosed in Phase 3 fr..
DJ
More news
Financials (USD)
Sales 2021 2 831 M - -
Net income 2021 450 M - -
Net cash 2021 2 027 M - -
P/E ratio 2021 42,0x
Yield 2021 -
Capitalization 18 093 M 18 093 M -
EV / Sales 2021 5,68x
EV / Sales 2022 4,39x
Nbr of Employees 1 773
Free-Float 98,8%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 106,87 $
Last Close Price 82,27 $
Spread / Highest target 75,0%
Spread / Average Target 29,9%
Spread / Lowest Target -14,9%
EPS Revisions
Managers and Directors
NameTitle
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-5.01%18 093
MODERNA, INC.53.57%64 417
LONZA GROUP AG-0.56%46 627
IQVIA HOLDINGS INC.29.20%44 366
CELLTRION, INC.-24.65%32 372
SEAGEN INC.-15.51%26 855